Growth inhibition in clonal subpopulations of a human epithelioid sarcoma cell line by retinoic acid and tumour necrosis factor alpha. by Engers, R. et al.
British Journal of Cancer (1996) 73, 491-498
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 M
Growth inhibition in clonal subpopulations of a human epithelioid sarcoma
cell line by retinoic acid and tumour necrosis factor alpha
R Engers', F van Roy2, T Heymerl, U Ramp', R Moll3, M Dienst1, U Friebel, A Pohl',
HE Gabbert' and C-D Gerharzl
'Institute ofPathology, Heinrich-Heine-University, Moorenstr. 5, 40225 Duesseldorf, Germany; 2Laboratory ofMolecular Biology,
University ofGent, Ledeganckstraat 35, 9000 Gent, Belgium; 3Institute ofPathology, Martin-Luther-University,
Magdeburgerstrasse 14, 06112 Halle, Germany.
Summary Epithelioid sarcoma is a highly malignant soft tissue tumour that is refractory to conventional
chemotherapy and irradiation. Since permanent cell lines of this tumour are extremely rare, in vitro data on
compounds with significant antiproliferative effects are still lacking. Therefore, we investigated the effects of
retinoic acid (RA) and tumour necrosis factor alpha (TNF-a) on tumour cell proliferation of three different
clonal subpopulations (GRU-1A, GRU-1B, GRU-1C) derived from the same human epithelioid sarcoma cell
line, GRU-1. In GRU-IA both RA (P=0.01) and TNF-a (P=0.002) exhibited highly significant and dose-
dependent growth inhibitory effects, which could further be increased by a combined application of both
compounds (P<0.006). GRU-1B proved to be sensitive to RA (P = 0.006), whereas no response to TNF-oa was
observed. GRU-1C was resistant to both RA and TNF-oa. The antiproliferative effect of TNF-a was mediated
by TNF receptor I(TNF-RI) and correlated positively with both the number of TNF-RI per cell and receptor
affinity. No correlation was detected between RA-induced growth inhibition and the expression pattern of the
RA receptors (RARs) RAR-a, RAR-fl, and RAR-y. Plating efficiency, however, could exclusively be reduced
by RA in GRU-1B, the only cell line expressing RAR-a. Taken together, these data are the first showing
significant antiproliferative effects in human epithelioid sarcoma by RA and TNF-a. Whereas the TNF-a
response seems to depend on the expression of TNF-RI, no simple correlation could be found between RA
sensitivity and the expression pattern of RARs.
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Epithelioid sarcoma is a malignant soft tissue tumour of
unknown histogenetic origin that in the past has often been
confused with other non-malignant and malignant lesions.
First described as a tumour entity by Enzinger (1970), the
morphological and ultrastructural characteristics have mean-
while been well documented. Little progress, however, has
been achieved in epithelioid sarcoma therapy. Since several
strategies of conventional chemotherapy and irradiation
proved to be ineffective (Prat et al., 1978; Chase and
Enzinger, 1985) the prognosis still remains poor when the
tumour is beyond the reach of curative surgery or has already
metastasised.
One important reason limiting the development of new
anti-cancerous strategies in epithelioid sarcoma therapy has
been the absence of an epithelioid sarcoma cell line, for a
long time preventing controlled investigations in vitro. To
date, only three human epithelioid sarcoma cell lines have
successfully been established (Reeves et al., 1987; Gerharz et
al., 1990; Sonobe et al., 1993) and data on drug sensitivity are
still scarce. Recently, we succeeded in establishing the human
epithelioid sarcoma cell line, GRU-1, (Gerharz et al., 1990),
which is characterised by a mixed mesenchymal-epithelial-
neural phenotype with co-expression of vimentin, cytokeratin
and neurofilament proteins. Subsequently, three clonal
subpopulations (GRU-1A, GRU-IB, and GRU-1C), differ-
ing in both morphological and biological characteristics have
been isolated from GRU-1 (Engers et al., 1994) reflecting
tumour heterogeneity, which is commonly accepted as an
important cause of drug resistance in tumour therapy.
Retinoic acid (RA) has been shown to exhibit pleiotropic
effects on malignant and non-malignant cells. Thus, RA
induced terminal differentiation in different tumour cell lines
and also affected tumour cell invasion, metastasis and
proliferation (Gabbert et al., 1988; McGarvey et al., 1990;
Gerharz et al., 1993). These effects are thought to be
mediated by two different classes of nuclear retinoid
receptors: retinoic acid receptors (RARs) and retinoid X
receptors (RXRs) (Chambon, 1993; Mangelsdorf, 1994).
TNF-a is known to be a pleiotropic cytokine, capable of
eliciting a wide variety of biological responses, which are
mediated by two different receptors, TNF-R1 and TNF-R2
of 55 kDa and 75 kDa respectively (Tartaglia and Goeddel,
1992; Sidhu and Bollon, 1993). Among these biological
effects, cytotoxic and cytostatic effects on diverse malignant
cell lines in vitro (Sugarman et al., 1985; Rutka et al., 1988;
Pusztai et al., 1993; Beyaert and Fiers, 1994) suggested a
possible clinical use for TNF-oa either alone or in combination
with other compounds. Recent in vivo studies on several
tumours revealed encouraging results when TNF-cx was
combined with other cytokines or with conventional
chemotherapy (Lejeune et al., 1994a,b). Little, however, is
known about a combined application of TNF-cx and RA.
The present study, therefore, was undertaken to investigate
the effects of RA and TNF-a on the tumour cell proliferation
of three different clonal subpopulations derived from the
human epithelioid sarcoma cell line GRU-1. Furthermore, we
tried to correlate the effects of RA and TNF-a with the
expression pattern of their receptors.
Materials and methods
Isolation of clonal subpopulations, cell culture and compounds
The clonal cell lines GRU-1A, GRU-1B and GRU-1C used
in this study were isolated from the epithelioid sarcoma cell
line GRU-1 as described previously (Engers et al., 1994).
L929s, L929sAneg, L929sATmTNFWTC3 and L929M1.1
high prod cell lines, known to produce different amounts of
TNF-c, were kindly provided by Dr B Vanhaesebroeck,
University of Gent (Vanhaesebroeck et al., 1991, 1992). All
cell lines were maintained in Dulbecco's modified Eagle
medium (DMEM; Gibco, Germany) supplemented with 10%
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fetal calf serum (FCS) and antibiotics. The same batch of
FCS was used to eliminate any possible changes in quality.
All-trans-retinoic acid (RA), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) and dimethyl sulph-
oxide (DMSO) were purchased from Sigma (Germany).
Human recombinant TNF-c and ['25I]TNF-a were kindly
provided by Knoll (Germany). All experiments for RA effects
were performed under light protection in order to avoid
inactivation and production ofunknown metabolites by light.
Immunocytochemistry
For immunocytochemistry, tumour cells were seeded on
microscope slides and incubated in standard growth medium
or medium supplemented with 0.1 UMm or 1 gM RA
respectively for 5 days. This incubation time was chosen for
two reasons: (1) in several other cell lines an incubation
period of 5 days has been shown to be sufficient for RA-
induced differentiation (Gabbert et al., 1988; Halevy and
Lerman, 1993); (2) a significant antiproliferative effect of RA,
which has been shown to go in parallel with differentiation
induction in other tumour models (Gabbert et al., 1988), was
observed after 5 days in our epithelioid sarcoma cell lines.
Afterwards, the tumour cells were fixed in situ by exposure to
methanol (5 min) and acetone (10 s) at -200C and then air
dried. Primary monoclonal antibodies against vimentin (Pitz
et al., 1987), cytokeratin 18 (Moll et al., 1988) or
neurofilament proteins (Debus et al., 1983) were applied to
the slides and allowed to incubate for 30 min at room
temperature in a moist chamber. After rinsing in phosphate-
buffered saline (PBS) the slides were incubated with the
secondary antibodies for 30 min. Slides were rinsed in PBS,
transferred to 95% ethanol (5 min) and air dried. The
number of positive tumour cells in five randomly selected
areas of the same size-was determined and related to the total
number of tumour cells in these areas. Values were well-
rounded.
Plating efficiency
Tumour cells were seeded into triplicate 96-microwell plates
(Gibco) at definite cell concentrations (1 and 10 cells per
microwell) and definite concentrations of RA (0.1 and 1 MM)
and TNF-ax (1, 10 or 100 ng ml-'). Cells were incubated for 2
and 4 weeks in a moist atmosphere of 5% carbon dioxide.
The plating efficiency was determined as the ratio of
microwells with visible colonies related to the number of
microwells inoculated with tumour cells.
MTT-assay
Growth inhibitory effects of RA and TNF-a were determined
by means of the colorimetric MTT assay, which is based on
reduction of MTT by a mitochondrial succinyl dehydrogen-
ase in viable cells and has been shown to be a valuable
method of addressing this purpose (Alley et al., 1988;
Scudiero et al., 1988). Tumour cells (5000) in 100 pl
standard growth medium were inoculated into each well of
triplicate 96-microwell plates (Gibco), except for the first
column, which served as blank. After 24 h RA and/or TNF-a
were added to the desired final concentration resulting in the
total amount of 200 ,l medium per well. Column two served
as control, containing tumour cells in culture medium
(200 ,l) without any drug supplement. After an incubation
period of 120 h 0.25 mg of MTT dissolved in PBS (Serva,
Germany) was added to each well and incubated for another
4 h. Formazan crystals were dissolved by exposure to DMSO
for 10 min and colour intensity determined on a microculture
plate reader (Titertek Multiscan Plus MK II) at 570 nm.
Values were expressed as:
% viable cells =
Absorbance of test - absorbance of blank
Absorbance of control - absorbance of blank
Data of MTT assay were analysed by means of t-tests.
Receptor binding assay
The binding assay for TNF receptors was essentially
performed as described by Scheurich et al. (1987) with a
small modification. Briefly, cells were harvested by exposure
to 0.05% EDTA (Gibco) and washed three times. Triplicate
samples of 2 x 106 cells each were incubated for 2 h at 4°C
with various concentrations of [125I]TNF-cx (2-20 ng ml-') in
a total volume of 0.3 ml of PBS (Gibco) containing 2% fetal
calf serum and 0.02% sodium azide. In order to determine
non-specific binding, radiolabelled TNF-a was mixed with a
200-fold excess of the unlabelled homologue before the
addition of tumour cells. After incubation cells were washed
three times, transferred into counting vials and counted by
means of a gamma-counter (LKB-Beckmann, Germany). The
number of TNF receptors per cell and the dissociation
constant (Kd) were determined by Scatchard plot analysis.
Determination of TNF mRNA and TNF receptor mRNA
For Northern blot analysis aliquots of the epithelioid
sarcoma cell lines were kept at -70°C until RNA
preparation. Total cellular RNA was isolated by the
guanidine-thiocyanate method as described by Chomczyns-
ki and Sacchi (1987). The RNA concentration was
determined by photometry at 260 nm. The quality of total
cellular RNA was verified in an ethidium bromide-stained
agarose gel. Northern blot analysis was carried out with
25 Mg of RNA of each sample under denaturing conditions
with 1% formaldehyde-agarose gel. Before RNA transfer to
nylon membranes the gel was stained with ethidium bromide
and the equality of RNA amounts loaded in each lane was
verified under UV light and photographed. In a second
control step the complete RNA transfer from the gel to the
nylon membrane was again verified under UV light.
Afterwards, the RNA was hybridised with specific DNA
probes. The DNA was labelled by incorporation of[32P]dCTP
using an oligolabelling kit (Pharmacia, Germany). The probes
were obtained from the purified inserts of the following
plasmids, which were kindly provided by Dr K Pfizenmaier,
Germany: TNF-RI (pAD-CMV1), insert:Sall/Xba; TNF-R2
(pBluescript SK), insert: EcoRI; TNF-R2 (PCDM8), insert:
XhoI/ScaI; TNF-a (pBR322), insert: EcoRI. Hybridisations
were performed in 5 x SSC (1 xSSC=0.15 M sodium
chloride/0.015 M sodium citrate)/50% formamide/I x Den-
hardt's solution (1 x Denhardt's solution=0.02% bovine
serum albumin/0.02% Ficoll/0.02% polyvinylpyrrolidone)
and 100 Mg denatured salmon sperm DNA per ml at 42°C
for 18 h. Filters were washed in 2 x SSC/0.1% sodium
dodecyl sulphate for 30 min at room temperature and in
0.1 x SSX/0.1% sodium dodecyl sulphate for 60 min at 60°C.
Fluorography was carried out by exposure ofKodak X-Omat
films for 10 days to dried filters at - 70°C, in conjunction
with intensifying screens. All experiments were done twice
and the results could be reproduced.
Determination of RA recptors
RAR-a, RAR-f, and RAR-y expression were determined by
means of reverse transcriptase-PCR (RT-PCR). Total
cellular RNA was prepared according to Stallcup and
Washington (1983). PCR was run using RAR-specific primer
sets as described by Ferrari et al. (1994) for 30 cycles
(denaturation at 94°C for 1 min, primer annealing at 55°C
for 1 min, extension at 72°C for 1 min). PCR products were
transferred to a nylon membrane by Southern blotting. RAR-
specific oligonucleotides (RAR-a: 5'-CCT TGC TTT GTC
TGT CAG G-3'; RAR-,B: 5'-TGC ATC CTC CAG GAG -
AAA GCT-3'; RAR-y: 5'-GGG TCA GCT CTT GT-
G AAG GC-3') were radiolabelled at the 5'-end with
[y-32P]ATP using a commercially available T4 polynucleotide
kinase (Pharmacia). Southern blots were prehybridised at
50°C for at least 3 h in 5 x SSPE, 2 x Denhardt's solution,50 jug ml-' salmon sperm DNA, 50 jug ml-' Escherichia coli
tRNA and 0.1% sodium dodecyl sulphate (SDS). After
adding the radiolabelled oligonucleotide probes blots were
incubated at 50°C for 18-22 h, followed by two washes in
2 x SSPE, 0.05% SDS, 5 x SSPE, and 0.1% SDS. Subse-
quently, autoradiography was performed. The calculated
length of PCR products were 226 bp (RAR-a); 388 bp
(RAR-/); 351 bp (RAR-y) respectively.
Determination of TNFproduction
For quantitative determination of TNF-a production by
GRU-1A, GRU-1B and GRU-IC triplicate confluent
tumour cell cultures were exposed to serum-free culture
medium supplemented with 5 ,ug insulin ml-', 5 Mug of
transferrin and 5 pg of sodium selenite (Sigma). After 3
days, conditioned media were collected and concentrated by
ultrafiltration using Centriprep-10 and Centricon-10 centri-
fugal microconcentrator devices (Amicon, Germany) accord-
ing to the manufacturer's manual. The amount of TNF-a
was determined on WEHI164c113S cells in an 18 h assay in
the presence of 1 jug ml-' actinomycin D as described by
Vanhaesebroek et al, (1992). L929S, L929sAneg,
L929sATmTNFWTC3, and L929MI.lhigh prod cells
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known to produce different amounts of TNF-a (Vanhae-
sebroeck et al., 1991, 1992) were used in parallel as negative
and positive controls respectively. The obtained results were
calibrated with respect to both mouse and human TNF-c
standards using a Curve Fit program.
Results
In vitro morphology
Tumour cells of GRU-1A, GRU-IB, and GRU-IC exhibited
a mainly epithelial-like, polygonal appearance and grew
strictly anchorage-dependent as monolayers without evi-
dence of cells piling up. Immunohistochemically, major
differences could be detected in the quantitative expression
of cytokeratin 18, vimentin and neurofilament proteins
(Figure 1 and Table I). In order to investigate the effects of
RA on tumour cell differentiation as defined by the
distribution of these intermediate filaments, tumour cells
were incubated for 5 days in medium supplemented with
different concentrations of RA. As summarised in Table I, no
significant change in the quantitative distribution of
cytokeratin 18, vimentin and neurofilament proteins could
be detected in GRU-1A, GRU-1B, or GRU-IC.
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Figure 1 Immunocytochemistry ofGRU-IA (a, d, g), GRU-IB (b, e, h), and GRU-IC (c, f, i). Quantitative differences between the
three clonal cell lines could be detected for cytokeratin 18 (a-c) and neurofilament proteins (d-f), while vimentin (g-i) disclosed a
uniform reaction in all tumour cells of GRU-1A, GRU-lB and GRU-1C. The same expression pattern was observed after exposure
to culture medium supplemented with different concentrations of RA. Scale bars, 25,um.
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Plating efficiency
After an incubation period of 14 and 28 days in standard
growth medium or in medium supplemented with RA or
TNF-a respectively, plating efficiency was determined for the
clonal cell lines GRU-1A, GRU-IB and GRU-IC. As
summarised in Table II, RA was able to reduce plating
efficiency only in GRU-1B, whereas a similar reduction of
plating efficiency was not observed in GRU-1A and GRU-
1C. In contrast, TNF-oa successfully reduced plating efficiency
only in GRU-1A but not in GRU-1B. GRU-1C was affected
by TNF-a only in the highest concentration and only after an
incubation period of 28 days.
Effects of RA and/or TNF-x on tumour cell proliferation
(Figure 2)
Proliferation analysis by MTT assay revealed growth-
inhibitory effects for both RA and TNF -a in subpopulation
GRU-1A. Thus, exposure to RA-containing medium resulted
in a statistically significant dose-dependent growth inhibition
Table I Quantitative distribution of cytokeratin 18 (CK 18),
neurofilament proteins (NR 4) and vimentin in GRU-1A, GRU-
lB and GRU-1C
CK 18 NR 4 Vimentin
(%) (%) (%)
GRU-1A
Control <1 100 100
RA 0.1 gM 0 100 100
RA 1.0 gM 0 100 100
GRU-1B
Control <1 60 100
RA 0.1 pM 0 60 100
RA 1.0 gM <1 60 100
GRU-1C
Control 40 80 100
RA 0.1 gM 45 70 100
RA 1.0 gM 20 60 100
The distribution pattern of these intermediate filaments did not
significantly change by exposure to medium supplemented with
different concentrations ofretinoic acid.
to 82%+5% (0.1 4uM RA, P=0.03) or 71%+5.5% (1 jiM
RA, P=0.01) of the control (= 100%) after an incubation for
5 days in vitro. TNF-a proved to be even more effective than
RA, inhibiting tumour cell proliferation dose dependently to
72%+6% (TNF-a 1 ng ml-', P=0.02), 57%+11% (TNF-a
10 ng ml-', P=0.02) and to 49%+4% (TNF-a 100 ng ml-',
P = 0.002) of the control (= 100%) after exposure for 5 days.
The effects of each singly applied compound could
significantly be increased by combined exposure to both
compounds. A maximal growth-inhibitory effect was achieved
by the combination of RA (1 ,gM) and TNF-a (100 ng ml-'),
resulting in an inhibition of tumour cell proliferation to
40% +4% of the control (P= 0.001), which was significantly
more effective than the single application of RA (P =0.006)
and TNF-cx (P =0.0002) in equivalent concentrations.
GRU-1B cells proved to be sensitive only to RA, showing
a growth-inhibitory effect to 91% +3% (RA 0.1 IgM,
P=0.04) and 81% +3% (1 /iM RA, P=0.006) of the control
(= 100%). TNF-a, however, did not exhibit any effects on
tumour cell proliferation of GRU-1B. The effects of RA on
GRU-1B could not significantly be increased by a combined
application of RA and TNF-a regardless of the concentra-
tions used.
Unlike GRU-1A and GRU-1B, GRU-1C was resistant to
any concentration of RA or TNF-a, applied either alone or
in combination. Although differences to the control could be
detected, the combination of RA (1 gM) and TNF-a
(100 ng ml-') did not result in a significant antiproliferative
effect owing to high standard deviations, which could not be
reduced by five repeated assays.
TNF-a receptor binding assay (Figure 2)
Scatchard analysis revealed the highest number of TNF
receptors in the GRU-1A cell line (1999 receptors per cell),
while GRU-1B and GRU-1C exhibited 1063 receptors per cell
and 1024 receptors per cell respectively. Furthermore, binding
affinity could be shown to be essentially higher in GRU-1A
(Kd=3.9x 10-', r2=0.98) than in GRU-1B (Kd=7.6x 10-'1,
r2=0.98) and in GRU-1C (Kd= 8.5 x 10-10, r2=0.91).
Expression of TNF-RJ and TNF-R2
By Northern blot analysis all cell lines expressed TNF-R1
mRNA, whereas TNF-R2 mRNA was not detected at all
(Figure 3a). In accordance with the results obtained by
Table II Plating efficiency of GRU-lA, GRU-IB and GRU-1C in standard growth medium or medium supplemented with various
concentrations of RA or TNF-a respectively
Plating efficiency (%)
14 days 14 days 28 days 28 days
One cell/well Ten cells/well One cell/well Ten cells/well
GRU-1A
Control 5 38 9 77
RAO.1 gM 8 31 27 89
RAl.O pM 3 23 8 75
TNF-a 1 ng ml-1 2 22 3 65
TNF-a10 ng ml-1 1 6 3 23
TNF-ao100 ng ml-1 0 6 2 8
GRU-1B
Control 7 11 14 74
RAO.1 gM 0 4 2 48
RA1.O uM 0 2 4 38
TNF-oc 1 ng ml-1 4 20 10 75
TNF-a 10 ng ml-1 3 18 5 60
TNF-co100 ng ml-' 8 18 13 55
GRU-1C
Control 8 32 19 95
RAO.1 gM 6 29 20 94
RA1.O M 8 50 17 92
TNF-a 1 ng ml-' 16 33 28 82
TNF-a 10 ng ml-' 12 39 16 89
TNF-aO 100 ngml-1 5 34 7 53Growth inhibition in epitheliold sarcoma
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Scatchard analysis the strongest signal for TNF-R1 mRNA
was found in GRU-lA, whereas GRU-lB and GRU-lC
expressed TNF-R1 mRNA to a significantly lower extent, not
differing between these two cell lines. Since co-incubation of
GRU-IA cells in TNF-a and RA resulted in a significantly
stronger antiproliferative effect when compared with each
single compound, the effect of RA on the expression of TNF-
Rl mRNA was investigated, showing that an incubation
period of 5 days in 1 pM RA did not significantly influence
TNF-Rl mRNA expression.
TNFproduction
Conditioned media from GRU-lA, GRU-IB and GRU-1C
did not contain cytotoxic activity towards WEHI164c113S
cells, whereas conditioned media of L929sATmTNFWTC3
and L929M1.lhigh prod cells used as positive controls
exhibited marked cytotoxic activities in the range of
3.6 x 104-4.4 x 106 IU ml-'. Furthermore, no TNF-a
mRNA could be detected in GRU-1A, GRU-IB, or GRU-
IC as evidenced by Northern blot analysis (data not shown).
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Figure 3 (a) Expression of TNF-R1 and TNF-R2 mRNA in
GRU-IA (1, after incubation in 1gM RA for 5 days; 2, non-
treated GRU-1A cells), GRU-1B (3) and GRU-1C (4) as detected
by Northern blot analysis. (*Ethidium bromide-stained gel
showing equal amounts of RNA in each lane.) (b) Expression
of RAR-ac, RAR-fl, and RAR-y in GRU-1A (1), GRU-1B (2) and
GRU-1C (3) as determined by RT -PCR and subsequent
receptor-specific oligonucleotide hybridisation.
Expression of RA receptors
By RT-PCR and subsequent oligonucleotide hybridisation
(Figure 3b) RAR-oc could be detected exclusively in GRU-1B
whereas RAR-# was not expressed in any cell line. RAR-y
mRNA could be found in GRU-1A and GRU-1C but not in
GRU-1B.
Discussion
Since the first description of epithelioid sarcoma as a unique
entity by Enzinger in 1970, little progress has been achieved
in the therapy of this malignancy. At present, radical excision
or amputation is still regarded as the most effective way of
initial treatment, although there is a 63-77% rate of
recurrence after initial surgical procedure and a 45-58%
incidence ofmetastasis (Prat et al., 1978; Chase and Enzinger,
1985). Irradiation and conventional chemotherapy with
agents such as doxorubicin, vincristine, cytoxan, actinomycin
D and methotrexate as well as platinol, oncovin and
interferon have proved to be ineffective (Chase and
Enzinger, 1985).
The present study clearly shows that both RA and TNF-a
are able to exhibit significant antiproliferative effects on
epithelioid sarcoma in vitro, although the results differ
markedly between the three clonal subpopulations. Thus,
RA dose-dependently inhibited tumour cell proliferation of
GRU-1A and GRU-1B after an incubation period of 5 days,
whereas no effect was seen in GRU-1C. The effects of RA are
known to be mediated through two classes of nuclear retinoid
receptors: retinoic acid receptors (RARs) which bind all-trans
retinoic acid (RA), the compound used in our study; and
retinoid X receptors (RXRs), which bind 9-cis retinoic acid
with high affinity (Chambon, 1993; Mangelsdorf, 1994). Both
classes of receptors have been found to consist of at least
three different isoforms each (ax, fi, y), the functional impact
of these isoforms still far from being elucidated (Chambon,
1993; Mangelsdorf, 1994). In our tumour model RAR-a was
expressed only in GRU-1B, whereas RAR-fl was not detected
in any cell line. RAR-y was found in GRU-1A and GRU-1C.
No direct correlation, however, between the RA-induced
growth inhibition, observed in GRU-1A and GRU-1B, and
the expression pattern of RARs became evident. Similar
results have been reported by van der Leede et al. (1993) for
other tumour models. Interestingly in this context, a marked
reduction ofplating efficiency by RA was found exclusively in
GRU-1B, the only cell line expressing RAR-a, while GRU-
IA and GRU-1C proved to be resistant. Nevertheless, it
remains to be determined whether the association between
RAR-a expression and reduction of plating efficiency is
causative rather than coincidental.
In other tumour models growth-inhibitory effects of RA
have previously been. shown to be coupled with a
simultaneous induction of differentiation (Mummery et al.,
1984; Gabbert et al., 1988; Joyce and Steer, 1992). In spite of
significant growth-inhibitory effects, however, RA failed to
exhibit any differentiation-inductive effects in GRU-1A and
GRU-1B. Thus, immunohistochemical analysis revealed no
change in the distribution pattern of cytokeratin 18, vimentin
or neurofilament proteins, indicative for epithelial, mesench-
ymal and neural differentiation respectively. The uncoupling
of growth inhibition and differentiation induction observed in
GRU-1A and GRU-1B after exposure to RA could result
from the complexity of RA signal transduction pathways.
Thus, receptor heterodimerisation, which has recently been
reported to occur between RARs and RXRs (Marks et al.,
1992; Nagpal et al., 1993), may result in multiple mutually
distinct receptors, each of which presumably activates specific
target genes in the regulation of proliferation and differentia-
tion.
TNF-a exhibited a highly significant antiproliferative effect
in GRU-1A, whereas GRU-1B and GRU-1C proved to be
TNF-resistant. TNF-a is known to exhibit a multitude of
different effects upon binding to two distinct high-affinity
receptors, TNF-R1 and TNF-R2 (Tartaglia and Goeddel,
1992; Sidhu and Bollon, 1993), the specific functional impact
of each receptor type on growth regulation and cytotoxicity
still being under discussion (Heller et al., 1992; Tartaglia et
al., 1993; Grell et al., 1993; Higuchi and Aggarwal, 1994). In
our tumour model, however, the antiproliferative effect of
TNF-a was exclusively mediated by TNF-R1 since no TNF-
R2 mRNA was detectable. Furthermore, a positive correla-
tion between TNF-ax-induced growth inhibition and both the
number of TNF-R1 and receptor affinity became evident. In
addition, it was excluded on both the mRNA and protein
level that TNF resistance in GRU-1B and GRU-1C was due
to endogenous TNF-a production, as has been reported from
other tumour models (Vanhaesebroeck et al., 1992), since all
subpopulations of GRU-1 proved to be TNF negative.
Finally, it was shown that the combined exposure to RA
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and TNF-oa resulted in an additive rather than a synergistic
antiproliferative effect in GRU-lA. In accordance with this
observation, RA did not significantly alter TNF-R1 mRNA
expression in the same cell line, suggesting that the
antiproliferative effects of both compounds might be
mediated by independent signal transduction pathways.
In conclusion, RA and TNF-cx have been shown to exhibit
significant and in part additive growth-inhibitory effects in
human epithelioid sarcoma, the response, however, markedly
differing between the three clonal subpopulations of our
tumor model. The antiproliferative effects of TNF-a were
mediated by TNF-RI and correlated with both the number
of TNF-RI and receptor affinity. Therefore, the clonal
subpopulations GRU-1A, GRU-1B and GRU-1C provide
an excellent human in vitro model to investigate TNF
resistance and TNF signalling pathways as well as the
susceptibility of epithelioid sarcoma for new therapeutic
strategies, taking into account tumour heterogeneity.
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